Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model

Perfusion (United Kingdom)

Volumn 29, Issue 1, 2014, Pages 32-38

  Harvey, B ^a   Johnson, T N ^a   Yeomanson, D ^a   Mulla, H ^b   Mayer, A P ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

adult; children; CVVH; drug removal; in vitro study; intensive care; neonate

Indexed keywords

BICARBONATE; CEFTRIAXONE; HARTMANN SOLUTION; HEMOSOL BO; HUMAN ALBUMIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD PUMP; BODY WEIGHT; CONTINUOUS HEMOFILTRATION; DILUTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY BLOOD FLOW; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NEWBORN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RESERVOIR; ULTRAFILTRATION;

ADULT; CHILDREN; CVVH; DRUG REMOVAL; IN VITRO STUDY; INTENSIVE CARE; NEONATE;

ADULT; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CHILD, PRESCHOOL; HEMOFILTRATION; HUMANS; INFANT; INFANT, NEWBORN; MODELS, CARDIOVASCULAR;

EID: 84890897512     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659113497497     Document Type: Article

References (19)

1. Shaheen IS, Harvey B, Watson AR, Pandya HC, Mayer A, Thomas D. Continuous venovenous hemofiltration with or without extracorporeal membrane oxygenation in children. Pediatr Crit Care Med. 2007 ; 8: 362-365
2. van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000 ; 13: 144-166
3. Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy in children. Paediatr Drugs. 2004 ; 6: 4565
4. RCPCH Publications ; 2003 :
5. Kroh UF, Lennartz H, Edwards DJ, Stoeckel KJ. Pharmacokinetics of ceftriaxone in patients undergoing continuous venovenous hemofiltration. Clin Pharmacol. 1996 ; 36: 1114-1119
6. Golper TA, Marx MA. Drug dosing adjustments during continuous renal replacement therapies. Kidney International.. 1998 ; 66: 165-168
7. Giles L, Jennings A, Thomson A, et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous venovenous hemofiltration or hemodiafiltration. Crit Care Med. 2000 ; 28: 632-637
8. Bressollie F, Kinowski JM, de la, Coussaye JE, Wynn N, Eledjam JJ, Galtier M. Pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet. 1994 ; 26: 457-471
9. Kronfol NO, Lau AH, Barakat MM. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continous hemofiltration. ASAIO Trans. 1987 ; 33: 300-303
10. Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Cefepime and CRRT: in vitro permability of two CRRT membrane pharmokinetics in four critically ill patients. Clin Ther. 2005 ; 27: 559-608
11. Abichandani R, Pereira BJ. Effects of different doses in continuous venovenous haemofiltration on outcomes of acute renal failure: a prospective randomised trial: by Ronco C, Bellomo R, Homel B, Brendolan A, Dan M, Piccinni P, and La Greca G. Lancet. 2000 ; 355: 26-30
12. Westrope C, Morrison GC. High volume haemofiltration (CVVH) in the management of neonates with hyperammonaemia. Poster presentation PCRRT conference Lake Bouna Vista ; 2006 Florida, USA ; 2006..
13. Pletz MW, Rau M, Bulitta J, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother. 2004 ; 48: 3765-3772
14. Perry TR and, Schentag JJ. Clinical use of ceftriaxone: a pharmacokinetic pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet. 2001 ; 40: 685-694
15. Churchwell MD. Use of an in vitro model of renal replacement therapy systems to estimate extracorporeal drug removal. J Clin Pharmacol. 2012 ; 52: 35S - 44S
16. Trotman RL, Williamson JC, Shoemaker DM. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005 2005 ; 41: 1159-1166
17. Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012 ; 40: 1523-1528
18. Durward A, Mayer A, Skellet S, et al. Hypoalbuminemia in critically ill children: incidence, prognosis and influence on the anion gap. Arch Dis Child. 2003 ; 88: 419-422
19. Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the ceonate; assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009 ; 123: 609-613